RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward αvβ3-expressing endothelial cells

International Journal of Cancer

Volumn 112, Issue 2, 2004, Pages 279-285

  Schraa, Astrid J ^a   Kok, Robbert J ^b   Botter, Sander M ^a   Withoff, Sebo ^a   Meijer, Dirk K F ^b   De Leij, Lou F M H ^a   Molema, Grietje ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

v 3 integrin; Cytotoxic T lymphocytes; Immunotherapy; RGD peptide; Vascular targeting

Indexed keywords

CD3 ANTIGEN; TRANSCRIPTION FACTOR NFAT; VITRONECTIN RECEPTOR;

ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL KILLING; CONTROLLED STUDY; COVALENT BOND; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENDOTHELIUM CELL; GENE ACTIVATION; HUMAN; HUMAN CELL; IC 50; ISOTOPE LABELING; LEUKEMIA CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; REPORTER GENE; STATISTICAL SIGNIFICANCE; TARGET CELL; TUMOR BLOOD FLOW; VASCULAR ENDOTHELIUM;

ANTIBODIES; ANTIGENS, CD3; ENDOTHELIAL CELLS; HUMANS; IMMUNOTHERAPY; INTEGRIN ALPHAVBETA3; LEUKOCYTES, MONONUCLEAR; NEOPLASMS; OLIGOPEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 4544382190     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20413     Document Type: Article

References (25)

1. van Spriel AB, van Ojik HH, van de Winkel JG. Immunotherapeutic perspective for bispecific antibodies. Immunol Today 2000;8:391-7.
2. Ganss R, Hanahan D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res 1998;58:4673-81.
3. Wei Y, Wang Q, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu C, Huang M, Lou Y, Xiao F, He Q, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000;6:1160-6.
4. Lou YY, Wei YQ, Yang L, Zhao X, Tian L, Lu Y, Wen YJ, Liu F, Huang MJ, Kang B, Xiao F, Su JM, et al. Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin β3. Immunol Invest 2002;31:51-69.
5. Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002;195:1575-84.
6. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
7. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999;5:1032-8.
8. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-7.
9. Pfaff M, Tangemann K, Muller B, Gurrath M, Muller G, Kessler H, Timpl R, Engel J. Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIbβ3, αvβ3, and α5β1 integrins. J Biol Chem 1994;269:20233-8.
10. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology 1995;13:265-70.
11. 3 integrin directed therapeutics. Bioconjug Chem 2002;13:128-35.
12. Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK, de Leij LF, Molema G. Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer 2002;102:469-75.
13. Calogero A, Hospers GA, Kruse KM, Schrier PI, Mulder NH, Hooijberg E, de Leij LF. Retargeting of a T cell line by anti MAGE-3/ HLA-A2 alpha beta TCR gene transfer. Anticancer Res 2000;20:1793-9.
14. Kroesen BJ, Bakker A, Van Lier RA, The HT, de Leij LF. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28. Cancer Res 1995;55:4409-15.
15. Tax WJ, Willems HW, Reekers PP, Capel PJ, Koene RA. Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature 1983;304:445-7.
16. Hunter WM, Greenwood FC. Preparation of iodine-131 labeled growth hormone of high specific activity. Nature 1962;194:495-6.
17. van Kooyk Y, Figdor CG. Avidity regulation of integrins: the driving force in leukocyte adhesion. Curr Opin Cell Biol 2000;12:542-7.
18. Riesbeck K, Billstrom A, Tordsson J, Brodin T, Kristensson K, Dohlsten M. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells. Clin Diagn Lab Immunol 1998;5:675-82.
19. Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 2002;99:7009-14.
20. Bortoletto N, Scotet E, Myamoto Y, D'Oro U, Lanzavecchia A. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. Eur J Immunol 2002;32:3102-7.
21. Zheng L, Dengler TJ, Kluger MS, Madge LA, Schechner JS, Maher SE, Pober JS, Bothwell AL. Cytoprotection of human umbilical vein endothelial cells against apoptosis and CTL-mediated lysis provided by caspase-resistant Bcl-2 without alterations in growth or activation responses. J Immunol 2000;164:4665-71.
22. Manke O, Tesch H, Lorenzen J, Diehl V, Bohlen H. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses. Int J Cancer 2001;91:516-22.
23. Kroesen BJ, Buter J, Sleijfer DT, Janssen RA, van der Graaf WT, The TH, de Leij L, Mulder NH. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 1994;70:652-61.
24. Lamers CH, Bolhuis RL, Warnaar SO, Stoter G, Gratama JW. Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody. Int J Cancer 1997;73:211-9.
25. van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 2003;63:5595-600.